Mitochondrial-derived extracellular vesicles amplify endothelial NOS uncoupling via TLR9‑NADPH oxidase cross‑talk, driving arterial stiffness independent of classical oxidative stress

Background

Endothelial dysfunction initiates vascular aging through eNOS uncoupling caused by BH4 oxidation, elevated ADMA, arginase II activity, and reduced Niban phosphorylation[1,2,3]. These disturbances increase superoxide production, diminish NO bioavailability, and promote arterial stiffness measured by PWV[4,5]. The bidirectional relationship between dysfunction and stiffness creates a vicious loop[6]. Despite mechanistic promise, BH4 supplementation shows inconsistent clinical benefit, suggesting unaddressed contributors[7].

Hypothesis

Mitochondrial-derived extracellular vesicles (mtEVs) released from aged endothelial and smooth‑muscle cells carry oxidized mitochondrial DNA (mtDNA) and activate endothelial TLR9. TLR9 signaling potentiates NADPH oxidase (NOX2/NOX4) activity, generating superoxide that further oxidizes BH4 and sustains eNOS uncoupling. This mtEV‑TLR9‑NOX axis operates parallel to classical ROS sources and explains why antioxidant‑focused interventions fail to fully restore NO bioavailability in subsets of older adults.

Mechanistic Rationale

1. mtEV release increases with vascular senescence – senescent cells shed EVs enriched in damaged mtDNA[2]. Elevated mtEV cargo has been linked to inflammation in atherosclerosis, but its direct effect on eNOS coupling remains untested.
2. TLR9 activation amplifies NOX-derived superoxide – TLR9 signaling recruits MyD88 and TRAF6, leading to PKC‑dependent phosphorylation of NOX subunits[3]. This pathway synergizes with BH4 oxidation, shifting eNOS toward superoxide production.
3. Feedback to Niban and MAPK – NOX‑derived ROS inhibit Niban phosphorylation, relieving its suppression of MAPK cascades[3]. Sustained ERK/p38 activation drives expression of arginase II and ADMA, compounding the NO deficit.
4. Arterial stiffness as read‑out – Persistent superoxide reduces NO‑mediated vasodilation and promotes collagen cross‑linking in the media, raising PWV[4]. Because mtEVs act downstream of BH4 oxidation, their contribution to stiffness is not fully rescued by BH4 alone.

Testable Predictions

• Prediction 1: Plasma mtEV concentration (measured by CD63+/MTCO2+ particles) will correlate positively with PWV and inversely with plasma NOx metabolites, independent of traditional risk factors.
• Prediction 2: In aged mice, pharmacological inhibition of EV release (GW4869) or TLR9 antagonism (ODN TTAGGG) will reduce aortic superoxide, restore BH4/BH2 ratio, and lower PWV more effectively than BH4 supplementation alone.
• Prediction 3: Human subjects with PWV >11.5 m/s who exhibit high baseline mtEV levels will show minimal improvement in flow‑mediated dilation after BH4 folate therapy, whereas those with low mtEV will respond favorably.
• Prediction 4: Exogenous addition of isolated mtEVs from aged donors to cultured human endothelial cells will increase TLR9‑MyD88 signaling, NOX activity, and eNOS uncoupling; these effects will be blocked by TLR9 knockdown or NOX inhibitors.

Experimental Approach

1. Human cohort – recruit 150 adults aged 60‑80, measure PWV, plasma NOx, ADMA, arginase II, and isolate mtEVs for quantitative PCR of mtDNA lesions and flow cytometry. Use multivariate modeling to assess mtEV as predictor of PWV beyond clinical covariates.
2. Intervention trial – randomize high‑PWV participants to BH4/folate, BH4/folate + GW4869 (low dose), or placebo for 12 weeks. Primary outcome: change in PWV; secondary: plasma NOx, mtEV load, and inflammatory cytokines.
3. Mechanistic validation – treat HUVECs with mtEVs from senescent vs. young donors; assess TLR9 phosphorylation, NOX4 activity (lucigenin assay), BH4 oxidation (HPLC), and eNOS coupling (citrulline production). Use siRNA against TLR9 or NOX4 to confirm pathway specificity.
4. Animal proof‑of‑concept – administer mtEVs from old mice to young ApoE‑/‑ mice via tail‑vein; monitor PWV, endothelial NO production, and aortic collagen deposition. Rescue experiments with TLR9 antagonist.

Implications

If validated, the mtEV‑TLR9‑NOX axis would define a distinct endothelial aging endotype that explains heterogeneous responses to NO‑restorative therapies. It would also introduce mtEV load as a actionable biomarker and suggest that targeting EV biogenesis or TLR9 signaling could complement existing strategies to improve vascular resilience in older adults.